Hepatitis B Virus Genetic Variation and TP53 R249S mutation in patients with hepatocellular carcinoma in thailand

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 6, 2013, Pages 3555-3559

  Thongbai, Chureeporn ^a   Sa nguanmoo, Pattaratida ^a   Kranokpiruk, Pavanrat ^a   Poovorawan, Kittiyod ^a   Poovorawan, Yong ^a   Tangkijvanich, Pisit ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Aflatoxin; Hepatitis B; Hepatocellular carcinoma; Mutation; Thailand

Indexed keywords

EID: 84882595635     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.6.3555     Document Type: Article

References (31)

1. Bruix J, Sherman M (2005). Management of hepatocellular carcinoma. Hepatology, 42, 1208-36.
2. Chen BF, Liu CJ, Jow GM, et al (2006). High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology, 130, 1153-68.
3. Chen CH, Changchien CS, Lee CM, et al (2008). Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. J Infectious Diseases, 198, 1634-42.
4. Choi MS, Kim DY, Lee DH, et al (2007). Clinical significance of pre-S mutations in patients with genotype C hepatitis B virus infection. J Viral Hepat, 14, 161-8.
5. Chotiyaputta W, Lok AS (2009). Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol, 6, 453-62.
6. Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma--current status and perspectives. Asian Pac J Cancer Prev, 13, 743-52.
7. Gouas D, Shi H,Hainaut P (2009). The aflatoxin-induced TP53 mutation at codon 249 R249S: biomarker of exposure, early detection and target for therapy. Cancer letters, 286, 29-37.
8. Hsieh YH, Su IJ, Wang HC, et al (2004). Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis, 25, 2023-32.
9. Hunt CM, McGill JM, Allen MI, et al (2000). Clinical relevance of hepatitis B viral mutations. Hepatology, 31, 1037-44.
10. Hussain SP, Schwank J, Staib F, et al (2007). TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene, 26, 2166-76.
11. Jackson PE, Kuang SY, Wang JB, et al (2003). Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis, 24, 1657-63.
12. Kao JH, Chen PJ, Lai MY, et al (2003). Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology, 124, 327-34.
13. Kay A, Zoulim F (2007). Hepatitis B virus genetic variability and evolution. Virus Research, 127, 164-76.
14. Kim BK, Revill PA, Ahn SH (2011). HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther, 16, 1169-86.
15. Kirk GD, Lesi OA, Mendy M, et al (2005). 249ser TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene, 24, 5858-67.
16. Kuang SY, Jackson PE, Wang JB, et al (2004). Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci USA, 101, 3575-80.
17. Kuang SY, Lekawanvijit S, Maneekarn N, et al (2005). Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev, 14, 380-4.
18. Liu Y, Wu F (2010). Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect, 118, 818-24.
19. Malmassari SL, Deng Q, Fontaine H, et al (2007). Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope. Hepatology, 45, 1199-209.
20. Ortiz-Cuaran S, Villar S, Gouas D, et al (2013). Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a casecontrol study from Thailand. Cancer Letters, 331, 46-51.
21. Sa-Nguanmoo P, Tangkijvanich P, Thawornsuk N, et al (2010). Molecular epidemiological study of hepatitis B virus among migrant workers from Cambodia, Laos, and Myanmar to Thailand. J Med Virology, 82, 1341-9.
22. Suwannakarn K, Tangkijvanich P, Thawornsuk N, et al (2008). Molecular epidemiological study of hepatitis B virus in Thailand based on the analysis of pre-S and S genes. Hepatol Res, 38, 244-51.
23. Szymanska K, Chen JG, Cui Y, et al (2009). TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China. Cancer Epidemiol Biomarkers Prev, 18, 1638-43.
24. Szymanska K, Lesi OA, Kirk GD, et al (2004). Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer, 110, 374-9.
25. Takahashi K, Ohta Y, Kanai K, et al (1999). Clinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver disease. Archives of Virology, 144, 1299-308.
26. Villar S, Le Roux-Goglin E, Gouas DA, et al (2011). Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection. Environ Health Perspect, 119, 1635-40.
27. Villar S, Ortiz-Cuaran S, Abedi-Ardekani B, et al (2012). Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis. PLoS One, 7, 37707.
28. Wai CT, Fontana RJ (2004). Clinical significance of hepatitis B virus genotypes, variants, and mutants. Clin Liver Dis, 8, 321-52.
29. Wild CP,Montesano R (2009). A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Letters, 286, 22-8.
30. Yu MC,Yuan JM (2004). Environmental factors and risk for hepatocellular carcinoma. Gastroenterology, 127, 72-8.
31. Yuen MF, Tanaka Y, Shinkai N, et al (2008). Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut, 57, 98-102.